SCOTUS rules against Amgen in patent scope case; the CEO trying to resurrect Galapagos

Taking stock of the drug industry, from the lab to the medicine chest

May 18, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Supreme Court rules against Amgen in closely watched case over scope of patent claims The U.S. Supreme Court upheld a lower court ruling that Amgen failed to disclose sufficient information about patent claims for Repatha. By Ed Silverman STAT+ | In Belgium, a native son returns to resurrect the drugmaker Galapagos — and 'to get the trust back' Paul Stoffels, a 61-year-old biotech eminence in his native Belgium, wants to "win the trust back" at the beat-down drugmaker. By Damian Garde STAT+ | New Biden science agency ARPA-H launches first program, targeting bone regrowth The new ARPA-H agency announced its first official program would target bone and joint damage from osteoarthritis. By Sarah Owermohle and Brittany Trang Sammy Kimball for STAT Listen: The FTC v. Amgen, Sarepta's future, & Galapagos' turnaround Mizuho Securities' Jared Holz joins us to explain why federal regulators are suing to block Amgen's $28B merger with Horizon Therapeutics. By Damian Garde and Meg Tirrell and Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser